Muhammad Sarmad
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Muhammad Sarmad has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Maaz Amir
Department of Medicine, King Edward Medical University, Mayo Hospital, Lahore, Punjab, Pakistan
3 shared publications - Abdul Haseeb Hasan
Kigali Kigali City Oli Health Magazine Organization Kigali
2 shared publications - Ahmed Asif
King Edward Medical University, Lahore, Punjab
2 shared publications - Usama Ahmad
King Edward Medical University, Lahore, Punjab
2 shared publications - Affaf Mahmood
Shaikh Khalifa Bin Zayed Al Nahyan Medical and Dental College, Lahore, Punjab
1 shared publication - Affaf Shahid
Allama Iqbal Medical College, Jinnah Hospital, Lahore, Punjab, Pakistan
1 shared publication
Latest Publications
- 28 October 2026
- Published by Wolters Kluwer Health in Clinical Neuropharmacology
Indobufen Versus Aspirin in Acute Ischemic Stroke: A Systematic Review and Meta-Analysis
Background: Acute ischemic stroke (AIS) is a major cause of death and disability worldwide. Early antiplatelet therapy reduces recurrence and improves outcomes. Although aspirin is standard treatment, its use is limited by bleeding risk. Indobufen, a reversible cyclooxygenase inhibitor with shorter platelet inhibition, may offer a safer alternative. Objective: To compare the efficacy and safety of indobufen versus aspirin in patients with AIS. Methods: A systematic review and meta-analysis was performed according to PRISMA guidelines. PubMed, Embase, Cochrane Library, and ScienceDirect were searched through February 2026 for randomized controlled trials comparing indobufen with aspirin in adults with AIS. Primary outcomes were functional outcomes (modified Rankin Scale), neurological improvement (NIHSS) at 90 days, recurrent ischemic stroke at 90 days, and composite vascular events. Secondary outcomes included bleeding and other adverse events. Pooled estimates were calculated using fixed- or random-effects models based on heterogeneity. The risk of bias was assessed using Cochrane RoB 2.0. Results: Four randomized controlled trials (278 records screened) were included. Indobufen showed no significant difference versus aspirin in NIHSS improvement at 90 days (MD: 0.01, 95% CI: −0.07 to 0.09) or recurrent ischemic stroke (OR: 0.54, 95% CI: 0.05-5.61). However, indobufen significantly improved modified Rankin Scale outcomes (MD: −1.11, 95% CI: −1.32 to −0.90) and reduced moderate-to-severe bleeding at 3 months (OR: 0.57, 95% CI: 0.35-0.92). Conclusions: Indobufen provides efficacy comparable to aspirin, with better functional outcomes and lower short-term bleeding risk, supporting its potential as an alternative antiplatelet therapy in AIS. Larger, international, multicenter trials are warranted. Larger, high-quality, multicenter international trials are warranted to confirm these findings.
- 28 October 2026
- Published by Wolters Kluwer Health in Clinical Neuropharmacology
Indobufen Versus Aspirin in Acute Ischemic Stroke: A Systematic Review and Meta-Analysis
Background: Acute ischemic stroke (AIS) is a major cause of death and disability worldwide. Early antiplatelet therapy reduces recurrence and improves outcomes. Although aspirin is standard treatment, its use is limited by bleeding risk. Indobufen, a reversible cyclooxygenase inhibitor with shorter platelet inhibition, may offer a safer alternative. Objective: To compare the efficacy and safety of indobufen versus aspirin in patients with AIS. Methods: A systematic review and meta-analysis was performed according to PRISMA guidelines. PubMed, Embase, Cochrane Library, and ScienceDirect were searched through February 2026 for randomized controlled trials comparing indobufen with aspirin in adults with AIS. Primary outcomes were functional outcomes (modified Rankin Scale), neurological improvement (NIHSS) at 90 days, recurrent ischemic stroke at 90 days, and composite vascular events. Secondary outcomes included bleeding and other adverse events. Pooled estimates were calculated using fixed- or random-effects models based on heterogeneity. The risk of bias was assessed using Cochrane RoB 2.0. Results: Four randomized controlled trials (278 records screened) were included. Indobufen showed no significant difference versus aspirin in NIHSS improvement at 90 days (MD: 0.01, 95% CI: −0.07 to 0.09) or recurrent ischemic stroke (OR: 0.54, 95% CI: 0.05-5.61). However, indobufen significantly improved modified Rankin Scale outcomes (MD: −1.11, 95% CI: −1.32 to −0.90) and reduced moderate-to-severe bleeding at 3 months (OR: 0.57, 95% CI: 0.35-0.92). Conclusions: Indobufen provides efficacy comparable to aspirin, with better functional outcomes and lower short-term bleeding risk, supporting its potential as an alternative antiplatelet therapy in AIS. Larger, international, multicenter trials are warranted. Larger, high-quality, multicenter international trials are warranted to confirm these findings.
- Open Access
- 14 October 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (11) , 7399-7412
Comparative evaluation of IV ketorolac and IV paracetamol in laparoscopic surgeries: a systematic review and meta-analysis
Background: Effective postoperative pain control is essential for enhanced recovery after laparoscopic surgery. Intravenous ketorolac and paracetamol are widely used non-opioid agents in multimodal analgesia, but their relative efficacy and safety remain controversial. Methods: Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 guidelines, databases were searched through September 2025 for randomized and comparative studies of intravenous (IV) ketorolac versus IV paracetamol. Pooled effect estimates with 95% confidence intervals were calculated using RevMan 5.4. The primary outcome was postoperative visual analog scale (VAS) pain scores; secondary outcomes included the timing and use of rescue analgesia, hemodynamic parameters, and adverse events. Results: Eight studies encompassing 540 patients met inclusion criteria. IV ketorolac significantly reduced VAS scores at 2 hours (MD = −0.95; 95% CI: −1.17 to −0.74; P < 0.00001), 4 hours (MD = −0.99; 95% CI: −1.62 to −0.35; P = 0.002), and 8 hours (MD = −0.45; 95% CI: −0.78 to −0.13; P = 0.006) postoperatively compared with IV paracetamol. The time to first rescue analgesia was significantly longer with ketorolac (MD = 1.93; 95% CI: 1.26–2.61; P < 0.00001). Postoperative vomiting occurred less frequently with ketorolac, while other adverse events and hemodynamic parameters were comparable between the groups. Substantial statistical heterogeneity was present for some outcomes. Conclusion: Intravenous ketorolac provides better early postoperative analgesia and longer-lasting pain relief than intravenous paracetamol following laparoscopic surgery, without increased adverse events. Vomiting was also less frequent with ketorolac. Both agents showed acceptable short-term safety and may be used for multimodal, opioid-sparing analgesia guided by patient and procedural factors.
- 14 October 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (11) , 7399-7412
Open AccessComparative evaluation of IV ketorolac and IV paracetamol in laparoscopic surgeries: a systematic review and meta-analysis
Background: Effective postoperative pain control is essential for enhanced recovery after laparoscopic surgery. Intravenous ketorolac and paracetamol are widely used non-opioid agents in multimodal analgesia, but their relative efficacy and safety remain controversial. Methods: Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 guidelines, databases were searched through September 2025 for randomized and comparative studies of intravenous (IV) ketorolac versus IV paracetamol. Pooled effect estimates with 95% confidence intervals were calculated using RevMan 5.4. The primary outcome was postoperative visual analog scale (VAS) pain scores; secondary outcomes included the timing and use of rescue analgesia, hemodynamic parameters, and adverse events. Results: Eight studies encompassing 540 patients met inclusion criteria. IV ketorolac significantly reduced VAS scores at 2 hours (MD = −0.95; 95% CI: −1.17 to −0.74; P < 0.00001), 4 hours (MD = −0.99; 95% CI: −1.62 to −0.35; P = 0.002), and 8 hours (MD = −0.45; 95% CI: −0.78 to −0.13; P = 0.006) postoperatively compared with IV paracetamol. The time to first rescue analgesia was significantly longer with ketorolac (MD = 1.93; 95% CI: 1.26–2.61; P < 0.00001). Postoperative vomiting occurred less frequently with ketorolac, while other adverse events and hemodynamic parameters were comparable between the groups. Substantial statistical heterogeneity was present for some outcomes. Conclusion: Intravenous ketorolac provides better early postoperative analgesia and longer-lasting pain relief than intravenous paracetamol following laparoscopic surgery, without increased adverse events. Vomiting was also less frequent with ketorolac. Both agents showed acceptable short-term safety and may be used for multimodal, opioid-sparing analgesia guided by patient and procedural factors.
- Open Access
- 5 September 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (36) , e44232
Assessing the risk factors of permanent pacemaker implantation following mitral valve surgery: A systematic review and meta-analysis
Background: Mitral valve surgery is a widely performed intervention for the treatment of various mitral valve pathologies. Postoperative conduction disturbances may necessitate permanent pacemaker (PPM) implantation. This study aims to identify and quantify patient-related, cardiovascular, procedural risk factors, and risk score-based predictors of PPM implantation following mitral valve surgery. Methods: The conduct of this systematic review and meta-analysis followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses reporting guidelines. A systematic literature search was performed across PubMed, Cochrane Library, Google Scholar, and Embase, including studies published from inception until September 2024. Statistical analyses were conducted using RevMan 5.4 software. Results: The meta-analysis included 8 studies totaling 39,634 patients (PPM: 3417; no PPM: 36,217) and revealed multiple significant predictors of postoperative PPM implantation. Among demographics, advanced age (mean difference [MD] 3.54; P < .00001) and female sex (odds ratio [OR] 1.19; P < .00001) were found as independent risk factors. Comorbidities included hypertension (OR 1.71, P < .00001), diabetes (OR 1.96, P < .00001), renal disease (OR 1.96, P < .00001), preexisting atrial fibrillation (OR 1.82, P < .00001), prior stroke (OR 1.57, P < .00001), chronic lung disease (OR 1.38, P < .00001), peripheral vascular disease (OR 2.03, P = .01), and smoking history (OR 1.19, P < .0001). Cardiovascular predictors comprised mitral stenosis (OR 1.77, P <.00001), prior cardiac surgery (OR 1.48, P = .0002), New York Heart Association class III/IV (OR 1.38, P = .005), and New York Heart Association class I (OR 0.64, P = .03). Procedural factors showed longer cardiopulmonary bypass time (MD 9.89, P < .00001) and aortic cross-clamp duration (MD 11.96, P < .00001) increasing risk, along with concomitant atrial fibrillation ablation (OR 1.34, P = .002). Increased society of thoracic surgeons’ mortality risk (MD 1.14%, P = .04) and EuroScore (MD 2.16, P = .0005), both effectively predicted PPM need. Conclusion: This meta-analysis represents the first comprehensive evaluation of risk factors associated with PPM implantation in patients undergoing mitral valve surgery. Several significant risk factors have been identified, warranting further research to validate and expand upon these findings.
- 5 September 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (36) , e44232
Open AccessAssessing the risk factors of permanent pacemaker implantation following mitral valve surgery: A systematic review and meta-analysis
Background: Mitral valve surgery is a widely performed intervention for the treatment of various mitral valve pathologies. Postoperative conduction disturbances may necessitate permanent pacemaker (PPM) implantation. This study aims to identify and quantify patient-related, cardiovascular, procedural risk factors, and risk score-based predictors of PPM implantation following mitral valve surgery. Methods: The conduct of this systematic review and meta-analysis followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses reporting guidelines. A systematic literature search was performed across PubMed, Cochrane Library, Google Scholar, and Embase, including studies published from inception until September 2024. Statistical analyses were conducted using RevMan 5.4 software. Results: The meta-analysis included 8 studies totaling 39,634 patients (PPM: 3417; no PPM: 36,217) and revealed multiple significant predictors of postoperative PPM implantation. Among demographics, advanced age (mean difference [MD] 3.54; P < .00001) and female sex (odds ratio [OR] 1.19; P < .00001) were found as independent risk factors. Comorbidities included hypertension (OR 1.71, P < .00001), diabetes (OR 1.96, P < .00001), renal disease (OR 1.96, P < .00001), preexisting atrial fibrillation (OR 1.82, P < .00001), prior stroke (OR 1.57, P < .00001), chronic lung disease (OR 1.38, P < .00001), peripheral vascular disease (OR 2.03, P = .01), and smoking history (OR 1.19, P < .0001). Cardiovascular predictors comprised mitral stenosis (OR 1.77, P <.00001), prior cardiac surgery (OR 1.48, P = .0002), New York Heart Association class III/IV (OR 1.38, P = .005), and New York Heart Association class I (OR 0.64, P = .03). Procedural factors showed longer cardiopulmonary bypass time (MD 9.89, P < .00001) and aortic cross-clamp duration (MD 11.96, P < .00001) increasing risk, along with concomitant atrial fibrillation ablation (OR 1.34, P = .002). Increased society of thoracic surgeons’ mortality risk (MD 1.14%, P = .04) and EuroScore (MD 2.16, P = .0005), both effectively predicted PPM need. Conclusion: This meta-analysis represents the first comprehensive evaluation of risk factors associated with PPM implantation in patients undergoing mitral valve surgery. Several significant risk factors have been identified, warranting further research to validate and expand upon these findings.